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Abstract The p53 tumor suppressor protein is critically in-
volved in cell cycle regulation and programmed cell death.
Here we show that expression of the BH3-only protein ITM2Bs
is able to induce apoptotic cell death in p53+/+, as well as in
p533/3 cell lines. This cell death involves neither subcellular
redistribution of p53 nor transcriptional regulation of p53 target
genes such as Bax, Ras, Puma or Bcl-2. Together, our data
provide evidence for a p53-independent apoptotic role of
ITM2Bs.
' 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The Bcl-2 family proteins are central regulators of apopto-
sis because they integrate survival and death signals that are
generated outside and inside the cell [1,2]. Mutual interaction
between pro- and anti-apoptotic members determines whether
a cell will die or not. Thus, Bcl-2 members act like check-
points through which survival and death signals pass before
they determine the cell fate. The family is subdivided into two
classes: anti-apoptotic members such as Bcl-2 and Bcl-xL,
which protect cells from apoptosis, and pro-apoptotic mem-
bers, including multi-BH-containing proteins, as well as the
large group of BH3-only death proteins [3,4] to which
ITM2Bs can be assigned [5,6].
Integral membrane protein 2B (ITM2B) is a type II integral
membrane protein that is associated with chondrogenic di¡er-
entiation [7]. ITM2B belongs to a multiple gene family con-
taining, at least, two other members, ITM2A and ITM2C.
The three isoforms share 50% identity at the amino acid level,
with most of the similarity in the COOH-terminal domain.
Alternative splicing of ITM2B generates the long and short
forms of ITM2B. The short form, ITM2Bs, which contains
the BH3 domain of Bcl-2 family members, induces apoptosis
in interleukin (IL)-2-, but not in IL-4-stimulated cells [5,6].
Biochemical and confocal studies have demonstrated that as-
sociation of ITM2Bs with mitochondria correlates with loss of
mitochondrial membrane potential, release of cytochrome c
and, as a ¢nal consequence, induction of apoptosis. More-
over, the apoptosis-inducing activity of ITM2Bs correlates
with caspase-9 and caspase-3 activation [6].
Despite the central role in cell death, the mechanism of p53-
mediated apoptosis after cellular stress remains unclear. Cur-
rent evidence indicates that p53 induces cell death by a mode
of action involving transactivation of target genes and direct
signaling events that are transcription-independent [8,9]. Con-
cerning the transactivation mode, a diverse list of p53-regu-
lated genes are candidates for participating in p53-apoptotic
function. Evidence for an additional transcription-indepen-
dent pathway for p53-mediated apoptosis is accumulating.
In some cell types, p53-dependent apoptosis occurs in the
absence of gene transcription or protein synthesis [10^12].
Mitochondria are central integrators and transducers of
pro-apoptotic signals. A major reason for the central role of
mitochondria lies in their ability to store critical apoptotic
activators and e¡ectors of cell death in their intermembrane
space. These include cytochrome c, Smac/Diablo, EndoG and
¢nally apoptosis-inducing factor, which activates nuclear en-
donucleases and procaspase-2 and -9 [13^18]. Permeabiliza-
tion of mitochondrial membrane causes the release of these
activators and triggers the killing of the cell. It has recently
been shown that a fraction of induced p53 protein directly
translocates to mitochondria in response to death signals
from anticancer drugs [19,20]. This translocation is speci¢c
for p53-dependent apoptosis, but not for p53-independent ap-
optosis [19]. In this manuscript we describe that ITM2Bs in-
duces apoptosis independently of p53.
2. Materials and methods
2.1. Cells, lymphokines, antibodies and reagents
The murine T cell line TS1KL, positive for p53 expression, can be
propagated independently in IL-2, IL-4 or IL-9 [21]. Cells were cul-
tured in RPMI 1640 supplemented with 5% heat-inactivated fetal calf
serum (FCS), 2 mM glutamine, 10 mM HEPES, 0.55 mM arginine,
0.24 mM asparagine, 0.05 mM 2-mercaptoethanol (2-ME) and 5 ng/
ml of IL-2. HeLa cells were maintained in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) supplemented with 10% heat-inactivated FCS,
10 mM HEPES, 2 mM glutamine and 1 mM sodium pyruvate. K562
cells were cultured in DMEM supplemented with 10% heat-inacti-
vated FCS and 2 mM glutamine. THP1 cells were cultured in
RPMI supplemented with 10% heat-inactivated FCS, 2 mM gluta-
mine, 1 mM sodium pyruvate, 10 mM HEPES and 0.05 mM 2-ME.
K562 is a p53-de¢cient cell line derived from chronic myelogenous
leukemia and highly undi¡erentiated [22,23]. THP1 is an acute mono-
cytic leukemia cell line that has a 26-base deletion beginning at codon
174 of the p53 coding sequence thus lacking p53 [24]. HeLa is a
cervical adenocarcinoma cell line that expresses undetectable or very
low levels of p53 [25]. These cell lines were purchased from the ATCC
Biosource Center. Anti-p53, anti-Ras, anti-Bcl-2, anti-Bax and anti-
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Tim23 antibodies were purchased from Transduction Laboratories.
Anti-Puma antibody was from ProSci. Anti-tubulin antibody was
from Santa Cruz and anti-histone antibody from Sigma. Anti-
ITM2B serum has been previously described [5]. Lipofectamine was
from Invitrogen. DEAE dextran and ECL reagent were from Phar-
macia. Wild type (wt) and dominant negative p53 (DN, mutation at
amino acid 249) mutant were a kind gift from D. May, Pasteur In-
stitute, France.
2.2. Estimation of apoptosis by propidium iodide staining
Estimation of apoptosis was performed as previously described [26].
2.3. Transient transfection
Transfections were performed using DEAE dextran or lipofectam-
ine reagent. Cells in exponential growth were washed in TS bu¡er (25
mM Tris^HCl pH 7.4, 137 mM NaCl, 5 mM KCl, 0.7 mM CaCl2, 0.5
mM MgCl2, and 0.6 mM PO4HNa2). A total of 5 Wg of DNA, 750 Wl
of TS bu¡er and 750 Wl of freshly prepared DEAE dextran (1 mg/ml)
in TS bu¡er were mixed successively with cells and incubated at 37‡C
for 1 h, centrifuged and resuspended in 12 ml of RPMI 1640/5% FCS
supplemented with 5 ng/ml of IL-2. Cells were analyzed 20 h after
transient transfection. Lipofectamine transfection was done according
to the manufacturer’s protocol.
2.4. Western blot
Western blot was performed as previously described [27].
2.5. Nuclear extracts
Cells were resuspended for 2 min in bu¡er A (50 mM NaCl, 10 mM
HEPES pH 8, 0.5 mM sucrose, 1 mM EDTA, 0.5 mM spermidine,
0.15 mM spermine and 0.2% Triton X-100). Lysates were centrifuged
(4500Ug, 3 min, 4‡C). Nuclei were resuspended in 1 ml bu¡er B (50
mM NaCl, 10 mM HEPES pH 8, 25% glycerol, 0.1 mM EDTA, 0.5
mM spermidine and 0.15 mM spermine) and centrifuged (4500Ug,
3 min, 4‡C). Nuclear proteins were extracted at 4‡C for 30 min in
60 Wl of bu¡er C (350 mM NaCl, 10 mM HEPES pH 8, 25% glycerol,
0.1 mM EDTA, 0.5 mM spermidine and 0.15 mM spermine). Super-
natants were cleared by centrifugation (30 min, 4‡C, 4500Ug) and
stored at 380‡C. All bu¡ers were supplemented with protease inhib-
itors (Sigma cocktail).
2.6. Isolation of mitochondria and cytosolic (S-100) fraction
Mitochondria were isolated using the protocol described by Fleisch-
er et al. [5].
3. Results
3.1. ITM2Bs induces apoptosis independently of p53
We have previously shown the pro-apoptotic activity of
ITM2Bs via loss of mitochondrial membrane potential and
caspase activation [5,6]. Recently, some reports have described
BH3-only members as p53-independent or -dependent media-
tors of apoptosis. For this reason, we explore the impact of
the BH3-only protein ITM2Bs on p53-independent cell death.
ITM2Bs, p53wt and p53DN mutant were overexpressed in IL-
2-stimulated TS1KL cells. As shown in Fig. 1A, expression of
ITM2Bs in IL-2-stimulated cells results in a strong induction
of apoptosis, compared with the low level of apoptosis ob-
served in cells transfected with the empty vector (mock trans-
fectants). Expression of p53wt moderately induces apoptosis
in IL-2-stimulated cells, while co-expression of both ITM2Bs
and p53wt does not have a synergistic e¡ect. Moreover, co-
expression of p53DN and ITM2Bs does not result in a block-
age of the apoptotic activity of ITM2Bs. Expression of
p53DN alone does not induces apoptosis in IL-2-stimulated
cells (Fig. 1A). Expression of transfected ITM2Bs and p53
was con¢rmed by Western blot (Fig. 1B). The transcriptional
activity of transfected p53 was estimated by the induction of
Ras expression. This result suggests a p53-independent apo-
ptotic activity of ITM2Bs in TS1KL cells.
To con¢rm the ability of ITM2Bs to promote a p53-inde-
pendent apoptotic pathway, ITM2Bs, p53wt and Bad were
overexpressed in di¡erent cell lines negative for the expression
of p53. The HeLa cell line contain very low to undetectable
levels of p53wt [25], the THP1 cell line is negative for the
expression of p53 [24] and K562 represents a p53-de¢cient
cell line caused by frameshift mutation [22]. The absence of
p53 transcript was con¢rmed in THP1 by reverse transcription
polymerase chain reaction (data not shown). Expression of
ITM2Bs in HeLa cells results in a strong induction of apo-
ptosis, compared with the low level of apoptosis observed in
mock transfectants (Fig. 2A). Expression of p53wt moderately
induces apoptosis while co-expression of p53wt with ITM2Bs
does not increase the level of apoptosis induced by ITM2Bs
alone, suggesting that they do not act synergistically (Fig.
2A). Bad expression was used as positive control of apoptosis
induction. Expression of transiently transfected proteins was
con¢rmed by direct comparison of protein level in transfected
and mock controls. Similarly, expression of ITM2Bs in THP1
cells results in a signi¢cant induction of apoptosis, which is
not increased by the co-expression of p53wt and ITM2Bs
(Fig. 2B). A modest induction of apoptosis was detected
upon expression of p53wt alone (Fig. 3A). Expression of
transfected proteins was examined by Western blot.
Expression of ITM2Bs was also able to induce a high level
of apoptosis in p53 null K562 cells (Fig. 2C), compared with
the low level of apoptosis detected in mock transfectants. This
apoptotic response is not accelerated upon overexpression of
ITM2Bs and p53wt. Finally, and as previously described, a
low level of apoptosis was detected after expression of p53wt
[23]. Interestingly, almost no induction of apoptosis was de-
Fig. 1. p53-independent apoptotic activity of ITM2Bs in TS1KL
cells. A: Cells were transfected with ITM2Bs, p53wt, p53DN or the
empty vector (mock) using the DEAE dextran method and main-
tained after transfection in IL-2 for 20 h. Cells were washed, per-
meabilized and stained with propidium iodide. Samples were ana-
lyzed by £ow cytometry. Standard deviation is shown where n=4.
B: Expression of the transiently transfected ITM2Bs and p53 was
con¢rmed by direct comparison of protein level in mock and trans-
fected cells. The blot was probed with anti-tubulin as internal con-
trol of protein loading. Molecular weight of the corresponding pro-
teins is shown.
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tected upon overexpression of Bad (Fig. 2C). Expression of
transfected proteins was con¢rmed by Western blot. Taking
together, these results suggest a p53-independent cell death
pathway triggered by ITM2Bs in di¡erent p53 negative and
positive cellular models.
3.2. Relationship between ITM2Bs expression and p53 cellular
localization
Following IL-2 starvation, TS1KL cells cease to proliferate
and undergo apoptosis, showing around 40% of apoptotic
cells upon 24 h of growth factor deprivation [5]. To study
the e¡ect of IL-2 deprivation on p53 expression, TS1KL cells
were IL-2-stimulated or -deprived for di¡erent time periods
and total p53 expression was analyzed by Western blot. p53
was observed in control IL-2-stimulated cells and was similar
throughout the deprivation period analyzed, even upon 24 h
of IL-2 deprivation (Fig. 3). To determine the subcellular
localization of p53 upon ITM2Bs expression in TS1KL cells,
we isolated nuclear, mitochondrial and cytosolic (S-100) pro-
teins from IL-2-stimulated mock or ITM2Bs transfected cells.
Similar levels of p53 were detected in mitochondrial extracts
of mock or ITM2Bs-transfected cells (Fig. 3). In the same
direction, comparable levels of p53 were found in cytosolic
(S-100) or nuclear extracts of mock or ITM2Bs-expressing
cells (Fig. 3), showing the highest amount of p53 in the nu-
cleus. As internal control of proper protein fractionation pro-
cedure, membrane was probed with Tim23 (mitochondrial
marker), caspase-3 (cytosolic marker) and histones (nuclear
marker).
3.3. Transcriptional regulation via p53 is not involved in
ITM2Bs-induced apoptosis
The pro-apoptotic Bcl-2 family members Bax and Puma are
reported to be transcriptionally regulated by p53, as well as
Ras and Bcl-2, which have also been described as targets of
p53. In concordance, an increase of Bax, Puma and Ras pro-
tein expression was found in TS1KL cells following p53 over-
expression (Fig. 4A). In contrast to recent publications [28],
Bcl-2 expression was not modi¢ed upon p53 expression in
TS1KL cells. On the contrary, similar levels of Bax, Bcl-2
and Ras expression were detected in mock or ITM2Bs-ex-
pressing TS1KL cells (Fig. 4A) while Puma expression could
not be detected in both conditions. In the p53 null K562 cell
line, ITM2Bs could not induce Bax expression (Fig. 4B) and
no changes in Bcl-2 and Ras expression were observed follow-
ing p53 or ITM2Bs overexpression. Finally, we analyzed
whether ITM2Bs itself could be a p53-inducible gene. Fig.
4C shows that overexpression of p53 does not transcription-
ally activate ITM2Bs expression in IL-2-stimulated TS1KL
or in THP1 cells. As a positive control, IL-2-deprivation of
Fig. 2. Expression of ITM2Bs induces apoptosis in HeLa, THP1 and K562 cells. A: HeLa cells were transfected or co-transfected with
ITM2Bs, p53wt, Bad or the empty vector (mock) using the lipofectamine method and maintained in culture for 20 h after transfection. Apo-
ptosis positive cells were analyzed as in Fig. 1. Standard deviation is shown where n=3. Expression of the transiently transfected proteins was
con¢rmed by Western blot. Molecular weight of the corresponding proteins is shown. B: THP1 cells were transiently transfected or co-trans-
fected with ITM2Bs, p53wt, Bad or the empty vector (mock) using DEAE dextran and maintained after transfection for 20 h in culture me-
dium. Cells were washed, permeabilized and stained with propidium iodide. Standard deviation is shown where n=3. The blot was probed with
anti-tubulin as internal control of protein loading. C: K562 cells were transiently transfected or co-transfected with ITM2Bs, p53wt, Bad or the
empty vector (mock) using lipofectamine and maintained after transfection in culture medium for 20 h. Cells were analyzed as in Fig. 1. Stan-
dard deviation is shown where n=3.
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TS1KL cells induces ITM2Bs expression (Fig. 4D). Taken to-
gether, these results strongly suggest that ITM2Bs induces
apoptosis in a p53-independent manner since the expression
of several p53 target genes is not modi¢ed by ITM2Bs and
vice versa p53 itself seems not to be involved in the regulation
of ITM2Bs expression.
4. Discussion
The pathways governing apoptosis in mammalian cells are
complex and the pro- and anti-apoptotic variations regulating
cell viability change according to cell type and also between
normal and tumor cells [2,29,30]. We have identi¢ed ITM2Bs
as a novel p53-independent regulator of cell death. Expression
of the BH3-only protein ITM2Bs induces apoptosis in the IL-
2-stimulated murine T cell line TS1KL. ITM2Bs is also able to
trigger apoptosis in several p53 negative cell lines. We ob-
served a dramatic cell death induced by ITM2Bs in THP1,
HeLa and K562 cell lines, which clearly illustrates that the
p53 status is not a prerequisite for ITM2Bs-induced apopto-
sis. We also found that ITM2Bs promotes apoptosis in these
cells irrespective of Bcl-2. Expression of p53wt induces cell
death in the p53 positive TS1KL, as well as in the p53 negative
background THP1 and HeLa cells, but not in the K562 p53
null cell line. Our results show that expression of p53wt pro-
tein is compatible with continuous proliferation of the K562
cell line. The growth characteristics of p53wt-expressing K562
cells did not di¡er from that of mock cells, which is in agree-
ment with previous results [23].
It is believed that p53 protein with mutations at certain
amino acid residues loses its transactivation function [31].
Interestingly, other p53 mutants have gain of function in
some p53 null cell lines [32^34]. However, our studies propose
that the dominant negative p53 mutant R249S does not acti-
vate an apoptotic pathway in IL-2-stimulated TS1KL cells.
Recently, it has been shown that a fraction of p53 trans-
locates to mitochondria in response to death signals from
anticancer drugs [19,20]. This translocation seems to be spe-
ci¢c for p53-dependent apoptosis, but not for p53-indepen-
dent apoptosis. In agreement, we were not able to detect
translocation of p53 to the mitochondria upon ITM2Bs ex-
pression, con¢rming that ITM2Bs triggers apoptosis via a
p53-independent mechanism.
Many proteins have been shown to induce apoptosis inde-
pendently of p53, including p19Arf [35], the transcription fac-
tor E2F-1 [36], the papillomavirus E2 [37], c-Myc [38], the
adenovirus E4orf4 [39], the simian virus 40 small t antigen
[40] and Bcl-2 antisense oligonucleotides [41]. According toFig. 3. Expression of ITM2Bs does not modify the expression and
subcellular localization of p53. A: TS1KL cells were IL-2-stimulated
or -deprived for the indicated times and then lysed. Proteins were
separated by sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE), transferred to nitrocellulose, probed with anti-
p53 antibody and revealed using the ECL system. The blot was re-
probed with pan-Ras antibody as internal control of protein load-
ing. Similar results were obtained in three independent experiments.
Molecular weights of the corresponding proteins are shown. B: Nu-
clear, mitochondrial and cytosolic (S-100) proteins were isolated
from mock or ITM2Bs-transfected cells, separated by SDS^PAGE,
transferred to nitrocellulose and immunoblotted with anti-p53, anti-
Tim23 (mitochondrial marker), anti-caspase-3 (cytosolic marker)
and anti-histones (nuclear marker). Similar results were obtained in
three independent experiments. Molecular weight of the correspond-
ing proteins is shown.
Fig. 4. ITM2Bs does not modify expression of p53 target genes and
is not a direct transcriptional target of p53. TS1KL (A) and K562
(B) cells were transiently transfected or co-transfected with ITM2Bs,
p53wt or the empty vector (mock). Proteins were separated by
SDS^PAGE and blotted with anti-Bax, anti-ITM2Bs, anti-Bcl-2,
anti-Ras, anti-Puma, anti-tubulin and anti-p53. Protein bands were
detected using the ECL system. Similar results were obtained in two
independent experiments. Molecular weight of the corresponding
proteins is shown. C: TS1KL cells were transiently transfected with
p53wt or the empty vector (mock transfectants). Proteins were sepa-
rated by SDS^PAGE and blotted with anti-ITM2Bs. The blot was
probed with anti-tubulin as internal control of protein loading. Sim-
ilar results were obtained in three independent experiments. Molecu-
lar weight of the corresponding proteins is shown. D: Proteins from
IL-2-stimulated or -deprived cells were separated by SDS^PAGE
and blotted with anti-ITM2Bs and anti-Ras. Proteins were detected
as above. Similar results were obtained in three independent experi-
ments.
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our results, ITM2Bs may be included in this group of pro-
teins.
Depending on the cell type, p53-induced apoptosis either
requires transcriptional activation [42] or not [10,11]. The
presence of mutants that transactivate p53, but are defective
for apoptosis, suggests that p53 induces apoptosis through
transactivation-dependent and -independent mechanisms.
The pro-apoptotic Bcl-2 member Bax was the ¢rst apoptotic
factor to be identi¢ed as a target for p53 transactivation [43].
Interestingly, p53 also represses the expression of Bcl-2 and
other genes, contributing to the induction of apoptosis by
blocking survival signals [28]. The death receptor Fas was
shown to be induced by p53, suggesting that p53 may also
induce caspase activation through death receptor signaling
[44]. In contrast, overexpression of p53 in the murine T cell
line TS1KL is not able to induce ITM2Bs expression. In addi-
tion, no consensus binding sites for p53 were observed in the
ITM2Bs promoter, suggesting that ITM2Bs is not a direct
transcriptional target for p53. Moreover, we were not able
to detect activation of p53 target genes such as Bax, Ras or
Bcl-2 repression in ITM2Bs transfected TS1KL cells. Our re-
sults allow us to propose that a p53-independent apoptotic
pathway is involved in the cell death activity of ITM2Bs.
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